If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2021-09-14
SUPPLEMENTAL AND CLARIFICATION ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION
2021-09-13
DISCLOSEABLE TRANSACTION (1) COVID-19 VACCINES LICENSE AGREEMENT; (2) COLLABORATION AND LICENSE AGREEMENT; AND (3) SHARE ISSUANCE AGREEMENT IN RESPECT OF THE MANUFACTURE, DEVELOPMENT AND COMMERCIALIZATION OF COVID-19 VACCINES AND CERTAIN LICENSED PRODUCTS
2021-09-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED AUGUST 31, 2021
2021-08-30
VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
2021-08-30
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
2021-08-26
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FIRST PERSON DOSED IN GLOBAL PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY IN CHINA FOR METASTATIC UROTHELIAL CANCER
2021-08-16
DATE OF BOARD MEETING
2021-08-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED JULY 31, 2021
2021-08-05
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NMPA FOR PHASE 3 TRIAL OF XERAVATM FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
2021-07-29
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON TAIWAN FDA GRANTING PEDIATRIC AND RARE SEVERE DISEASE PRIORITY REVIEW DESIGNATION FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
